Delving into the Latest Updates on Mediclinic Middle East Holdings Ltd. with Synapse

Overview

Tags

Immune System Diseases

Digestive System Disorders

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	1

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) designed to directly block the interaction between PD-1 and its ligands and enable the T cell to remain active and co-ordinate an attack on tumor cells.
We hypothesise that the Clinical Benefit Rate (CBR) and progression free survival (PFS) of metastatic breast cancer patients who have ESR1 mutation will improve following administration of a combination of pembrolizumab and tamoxifen.

Start Date01 Aug 2019

Sponsor / Collaborator

Mediclinic Middle East Holdings Ltd.

100 Clinical Results associated with Mediclinic Middle East Holdings Ltd.

Login to view more data

0 Patents (Medical) associated with Mediclinic Middle East Holdings Ltd.

Login to view more data

6

Literatures (Medical) associated with Mediclinic Middle East Holdings Ltd.

01 Mar 2024·Nature Cell Biology

Distinct pathways drive anterior hypoblast specification in the implanting human embryo

Article

Author: Mania, Anastasia ; Vindel, Sandra Gutiérrez ; Barrie, Amy ; Gantner, Carlos W ; Weberling, Antonia ; Richardson, Lucy ; Cunningham, Paula ; Iwamoto-Stohl, Lisa K ; Elder, Kay ; Drezet, Cath ; Zernicka-Goetz, Magdalena ; Weavers, Lauren ; Christie, Leila ; Barnikel, Zoe ; Snell, Phillip ; Lockwood, Megan ; Chowdhury, Nabiha ; Oakley, Rebecca ; Efstathiou, Panagiota ; Fishel, Simon ; Campbell, Alison ; Weatherbee, Bailey A T ; Pretty, Catherine

AbstractDevelopment requires coordinated interactions between the epiblast, which generates the embryo proper; the trophectoderm, which generates the placenta; and the hypoblast, which forms both the anterior signalling centre and the yolk sac. These interactions remain poorly understood in human embryogenesis because mechanistic studies have only recently become possible. Here we examine signalling interactions post-implantation using human embryos and stem cell models of the epiblast and hypoblast. We find anterior hypoblast specification is NODAL dependent, as in the mouse. However, while BMP inhibits anterior signalling centre specification in the mouse, it is essential for its maintenance in human. We also find contrasting requirements for BMP in the naive pre-implantation epiblast of mouse and human embryos. Finally, we show that NOTCH signalling is important for human epiblast survival. Our findings of conserved and species-specific factors that drive these early stages of embryonic development highlight the strengths of comparative species studies.

29 Jun 2022·Human Reproduction

P-525 PGT-A with embryo pooling: does it result in a higher yield of euploid embryos and better clinical pregnancy outcomes?

Author: Al Najjar, R ; Emesrson, G ; Ahmad, E

AbstractStudy questionDoes PGT-A with embryo pooling result in a higher yield of euploid embryos and better clinical pregnancy outcomes compared to PGT-A done after one cycle?Summary answerThere is no evidence to support that embryo pooling for PGT-A purposes is favorable in preference to PGT-A after one cycle.What is known alreadyPGT-A has been the method of choice that is thought to optimize embryo selection and enhance clinical outcomes. However, the number of embryos available for biopsy can be a source of limitation, as the yield of euploid embryos suitable for transfer can be affected when lower number of embryos are available for screening. A protocol that is suggested to overcome this limitation is to undergo multiple IVF/ICSI cycles with blastocyst biopsy and embryo pooling, then proceed with PGT-A screening once a sufficient number of biopsied embryos is attained.Study design, size, durationThis is a retrospective study that included ICSI cycles from June 2019 to December 2021, involving 157 patients (average maternal age 36.4) that underwent PGT-A after one ICSI cycle (group A), and 79 patients (average maternal age 35.6 ) that underwent PGT-A after embryo pooling from more than one ICSI cycle (Group B). Patients in group B underwent pooling due to cost implications on the number of embryos to screen.Participants/materials, setting, methodsA total of 843 embryos were biopsied and screened for group A, and 536 were biopsied and screened for group B. Following PGT-A screening, a number of frozen embryo transfers (FET) were conducted (120, 67 respectively). Investigations included: number of embryos available for biopsy, number of euploid embryos and clinical pregnancy outcomes after FET. Statistical analysis was calculated (P < 0.05).Main results and the role of chancePatients in group A proceeded with PGT-A after only one ICSI cycle, while in group B patients underwent 2.3 cycles on average. The average number of embryos suitable for biopsy was 5.4, and 6.9 per patient respectively. The rate of euploid embryos was 42.1% and 43.8%, and the average number of euploid embryos per patient was 5.4 and 6.5 respectively. A total of 144 embryos were transferred in group A with an average of 1.2 embryos per patient. Clinical pregnancy rate (CPR) was 60%, implantation rate was 54.9% and live birth rate (LBR) was 35.8%. In Group B a total of 67 embryos were transferred with an average of 1.1 embryos per patient. Clinical pregnancy rate (CPR) was 67.7%, implantation rate was 68.7% and live birth rate (LBR) was 40%. No significant difference was observed between both groups for clinical outcomes (P > 0.05).Limitations, reasons for cautionThis study is retrospective and small in size. Data on live birth rate requires further follow up as a number of patients are still in ongoing pregnancies. A larger data set study is needed to support conclusion.Wider implications of the findingsResults from this study does not support the adoption of a pooling strategy for patients undergoing PGT-A. Although the number of embryos available for biopsy may increase slightly, the yield of euploid embryos is not significantly increased and the clinical pregnancy rate is not enhanced.Trial registration numbernot applicable

01 Feb 2021·Fertility and Sterility

WITHDRAWN: Growth hormone improves insulin-like growth factor 1 and steroid hormone levels in follicle fluid, expression of hormone receptors in granulosa cells, and in vitro fertilization outcomes of poor ovarian responders

Article

Author: Lai, Wei ; Zhang, Yanan ; Liu, Weixin ; Verwoerd, Gideon ; Gong, Yan ; Zhang, Kun

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

100 Deals associated with Mediclinic Middle East Holdings Ltd.

Login to view more data

100 Translational Medicine associated with Mediclinic Middle East Holdings Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data